Enliven Therapeutics, Inc. (ELVN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29337E1029
Enliven Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -119.66 m USD |
| EBIT | -103.69 m USD |
| Net income | -103.69 m USD |
| Diluted EPS – continuing operations | -1.83 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
More stocks
- Regis Resources Ltd (RRL.AX)
- Zhejiang Huazheng New Material (603186.SS)
- Farsoon Technology Co. Ltd. A (688433.SS)
- Anhui Zhongding Sealing Parts Co Ltd (000887.SZ)
- Sparebank 1 Sorost-Norge (SOON.OL)
- Nitto Boseki Co Ltd (3110.T)
- SLM Corp (SLM)
- JA Solar Technology Co Ltd (002459.SZ)
- NMI Holdings, Inc. (NMIH)
- Dosilicon Co Ltd (688110.SS)
- Ambu A/S (AMBU B.CO)
- Nagase & Co Ltd (8012.T)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.